Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of CNS diseases, has received a third patent (number 8,663,683) from the United States Patent and Trademark Office (USPTO) recently covering Trokendi XR, its novel once-daily extended-release topiramate product.  It provides protection for the product with expiration that is no earlier than 2027.

"We continue to place great importance on expanding and protecting our intellectual property to ensure the sustainability and longevity of our products. The issuance of this patent provides us with a broadened proprietary position with respect to our extended release formulation of topiramate. We now have patent protection on Oxtellar XR and Trokendi XR through three issued US patents each, and are focused on further expanding such protection," said Jack A. Khattar, president and CEO of Supernus.

Supernus has several additional patent applications for extended-release topiramate and extended-release oxcarbazepine pending in other geographic regions.

Trokendi XR is the only approved novel once-daily extended release formulation of topiramate for the treatment of epilepsy. Trokendi XR is an antiepileptic drug indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures; and adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome. The product is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.